Intra-hospital differences in antibiotic use correlate with antimicrobial resistance rate in Escherichia coli and Klebsiella pneumoniae: a retrospective observational study.
Fiche du document
2018
- doi: 10.1186/s13756-018-0387-0
- issn: 2047-2994
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1186/s13756-018-0387-0
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30069305
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2047-2994
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_F23661217F6A9
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Tsʻeu Tzʻu Ci Tse Group dynamics Association Groups, SocialCiter ce document
A. Cusini et al., « Intra-hospital differences in antibiotic use correlate with antimicrobial resistance rate in Escherichia coli and Klebsiella pneumoniae: a retrospective observational study. », Serveur académique Lausannois, ID : 10.1186/s13756-018-0387-0
Métriques
Partage / Export
Résumé
Monitoring antimicrobial use and resistance in hospitals are important tools of antimicrobial stewardship programs. We aimed to determine the association between the use of frequently prescribed antibiotics and the corresponding resistance rates in Escherichia coli and Klebsiella pneumoniae among the clinical departments of a tertiary care hospital. We performed a retrospective observational study to analyse the use of nine frequently prescribed antibiotics and the corresponding antimicrobial resistance rates in hospital acquired E. coli and K. pneumoniae isolates from 18 departments of our institution over 9 years (2008-2016). The main cross-sectional analysis assessed the hypothetical influence of antibiotic consumption on resistance by mixed logistic regression models. We found an association between antibiotic use and resistance rates in E. coli for amoxicillin-clavulanic acid (OR per each step of 5 defined daily dose/100 bed-days 1.07, 95% CI 1.02-1.12; p = 0.004), piperacillin-tazobactam (OR 2.11, 95% CI 1.45-3.07; p